Volitionrx (VNRX) Net Income towards Common Stockholders (2019 - 2025)
Volitionrx (VNRX) has disclosed Net Income towards Common Stockholders for 9 consecutive years, with -$5.1 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Net Income towards Common Stockholders rose 12.38% year-over-year to -$5.1 million, compared with a TTM value of -$16.4 million through Sep 2025, up 45.15%, and an annual FY2024 reading of -$27.0 million, up 23.65% over the prior year.
- Net Income towards Common Stockholders was -$5.1 million for Q3 2025 at Volitionrx, down from $29992.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $94092.0 in Q4 2022 and bottomed at -$9.5 million in Q2 2023.
- Average Net Income towards Common Stockholders over 5 years is -$3.8 million, with a median of -$5.1 million recorded in 2025.
- The sharpest move saw Net Income towards Common Stockholders soared 791.1% in 2022, then plummeted 12177.49% in 2023.
- Year by year, Net Income towards Common Stockholders stood at $73088.0 in 2021, then grew by 28.74% to $94092.0 in 2022, then crashed by 9344.41% to -$8.7 million in 2023, then soared by 33.4% to -$5.8 million in 2024, then grew by 11.95% to -$5.1 million in 2025.
- Business Quant data shows Net Income towards Common Stockholders for VNRX at -$5.1 million in Q3 2025, $29992.0 in Q2 2025, and -$5.5 million in Q1 2025.